Autologous Platelet Enriched Gel Versus Metalloproteinase Inhibitor in the Healing of Chronic Lower Leg Ulcers
NCT ID: NCT00658983
Last Updated: 2023-01-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
18 participants
INTERVENTIONAL
2008-04-01
2010-08-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment Outcome of Autologous PRP Versus Conventional Therapy Among Patients With Chronic Venous Leg Ulcers
NCT05974982
PluroGel on Wounds of Mixed Etiology
NCT03275831
A Clinical Study to Assess a Compression Device in Patients With Venous Leg Ulcers
NCT02561013
A Randomized, Controlled Trial of Autologous Platelet Gel Treatment in Diabetic Foot Ulcers
NCT00338702
Biatain Ag vs Biatain in the Treament of Leg Ulcers
NCT00807664
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Autologous Platelet Enriched Gel
Autologous Platelet Enriched Gel
Treatment with Autologous Platelet Enriched Gel
2
Metalloproteinase Inhibitor (Promogran)
Metalloproteinase Inhibitor
Treatment with Metalloproteinase Inhibitor (Promogran)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Autologous Platelet Enriched Gel
Treatment with Autologous Platelet Enriched Gel
Metalloproteinase Inhibitor
Treatment with Metalloproteinase Inhibitor (Promogran)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* A non-healing chronic lower leg ulcer
* Platelet ranges of 150000 per ml circulating blood
Exclusion Criteria
* Hypersensitive to collagen regenerated cellulose
* Hemodynamic unstable patient
* Hypercoagulability
* Heart decompensation or angina pectoris
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medtronic
INDUSTRY
Johnson & Johnson
INDUSTRY
University Hospital, Ghent
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wim Bongaerts, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Ghent
Wouter De Moor
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Ghent
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Ghent
Ghent, , Belgium
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008/049
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.